Elevation Oncology Key Executives
This section highlights Elevation Oncology's key executives, including their titles and compensation details.
Find Contacts at Elevation Oncology
(Showing 0 of )
Elevation Oncology Earnings
This section highlights Elevation Oncology's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
$0.24
Stock Price
$14.34M
Market Cap
34
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for Elevation Oncology, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $39.00K | $27.00K | $18.00K | $15.00K |
| Gross Profit | $- | $-39.00K | $-27.00K | $-18.00K | $-15.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $28.60M | $25.43M | $78.72M | $23.59M | $15.48M |
| General and Administrative Expenses | $16.11M | $14.90M | $15.83M | $8.45M | $1.80M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $16.11M | $14.90M | $15.83M | $8.45M | $1.80M |
| Other Expenses | $- | $5.11M | $-506.00K | $7.00K | $11.00K |
| Operating Expenses | $44.70M | $45.45M | $94.55M | $32.05M | $17.28M |
| Cost and Expenses | $- | $45.45M | $94.55M | $32.05M | $17.28M |
| Interest Income | $- | $3.90M | $- | $- | $- |
| Interest Expense | $1.20M | $4.17M | $479.00K | $- | $- |
| Depreciation and Amortization | $- | $39.00K | $27.00K | $18.00K | $15.00K |
| EBITDA | $-44.70M | $-41.47M | $-94.52M | $-32.03M | $-17.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-44.70M | $-45.45M | $-94.55M | $-32.05M | $-17.28M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $261.00K | $-229.00K | $-506.00K | $7.00K | $11.00K |
| Income Before Tax | $-44.44M | $-45.67M | $-95.06M | $-32.04M | $-17.27M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $43.00K | $30.00K | $25.00K | $-218.56K | $-191.30K |
| Net Income | $-44.48M | $-45.70M | $-95.08M | $-32.04M | $-17.27M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.78 | $-1.34 | $-4.09 | $-1.38 | $-0.73 |
| EPS Diluted | $-0.78 | $-1.34 | $-4.09 | $-1.38 | $-0.73 |
| Weighted Average Shares Outstanding | 57.28M | 34.08M | 23.27M | 23.21M | 23.76M |
| Weighted Average Shares Outstanding Diluted | 57.28M | 34.08M | 23.27M | 23.21M | 23.76M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $58.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $5.00K | $4.00K | $10.00K | $10.00K | $9.00K | $10.00K | $10.00K | $10.00K | $8.00K | $5.00K | $4.00K | $5.00K | $3.00K | $6.00K | $4.00K | $- | $- | $- | $- |
| Gross Profit | $- | $-5.00K | $-4.00K | $-10.00K | $48.00K | $-9.00K | $-10.00K | $-10.00K | $-10.00K | $-8.00K | $-5.00K | $-4.00K | $-5.00K | $-3.00K | $-6.00K | $-4.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 82.80% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $6.65M | $9.39M | $6.55M | $6.01M | $4.69M | $7.42M | $6.03M | $7.29M | $14.50M | $34.34M | $16.30M | $13.57M | $6.25M | $9.30M | $3.91M | $4.13M | $8.43M | $2.55M | $3.00M | $1.49M |
| General and Administrative Expenses | $4.00M | $3.84M | $4.41M | $3.86M | $3.25M | $3.50M | $3.81M | $4.35M | $4.04M | $4.19M | $3.81M | $3.79M | $3.38M | $2.98M | $1.15M | $952.00K | $453.00K | $462.00K | $414.00K | $471.00K |
| Selling and Marketing Expenses | $- | $- | $-4.00K | $3.84M | $-10.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.00M | $3.84M | $4.41M | $3.85M | $3.25M | $3.50M | $3.81M | $4.35M | $4.04M | $4.19M | $3.81M | $3.79M | $3.38M | $2.98M | $1.15M | $952.00K | $453.00K | $462.00K | $414.00K | $471.00K |
| Other Expenses | $- | $- | $- | $- | $56.00K | $295.00K | $-271.00K | $-309.00K | $-480.00K | $-306.00K | $187.00K | $93.00K | $2.00K | $10.00K | $- | $-5.00K | $-3.00K | $1.00K | $12.00K | $1.00K |
| Operating Expenses | $10.64M | $13.23M | $10.96M | $9.86M | $7.94M | $10.92M | $9.83M | $11.64M | $18.54M | $38.53M | $20.11M | $17.37M | $9.62M | $12.28M | $5.06M | $5.09M | $8.89M | $3.01M | $3.42M | $1.96M |
| Cost and Expenses | $10.64M | $13.23M | $10.96M | $9.87M | $7.95M | $10.92M | $9.83M | $11.64M | $18.54M | $38.53M | $20.11M | $17.37M | $9.62M | $12.28M | $5.06M | $5.09M | $8.89M | $3.01M | $3.42M | $1.96M |
| Interest Income | $- | $- | $- | $- | $3.90M | $- | $234 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $513.00K | $115.00K | $4.17M | $- | $- | $309.00K | $470.00K | $306.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $5.00K | $5.00K | $4.00K | $10.00K | $10.00K | $9.00K | $10.00K | $10.00K | $10.00K | $8.00K | $5.00K | $4.00K | $5.00K | $3.00K | $6.00K | $4.00K | $15.00K | $3.01M | $3.42M | $1.96M |
| EBITDA | $-6.38M | $-13.22M | $-10.96M | $-9.86M | $-7.94M | $-10.91M | $-9.82M | $-11.63M | $-18.54M | $-38.52M | $-20.11M | $-17.36M | $-9.62M | $-12.27M | $-5.05M | $-5.08M | $-8.87M | $- | $- | $- |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13682.76% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-10.64M | $-13.23M | $-10.96M | $-9.87M | $-7.95M | $-10.92M | $-9.83M | $-16.75M | $-18.54M | $-38.53M | $-20.11M | $-17.37M | $-9.62M | $-12.28M | $-5.06M | $-5.09M | $-8.89M | $-3.01M | $-3.42M | $-1.96M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13700.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $215.00K | $360.00K | $513.00K | $-827.00K | $56.00K | $295.00K | $-271.00K | $-309.00K | $-480.00K | $-306.00K | $187.00K | $93.00K | $2.00K | $10.00K | $- | $-5.00K | $-3.00K | $1.00K | $12.00K | $1.00K |
| Income Before Tax | $-10.43M | $-12.87M | $-10.45M | $-10.70M | $-7.89M | $-10.62M | $-10.11M | $-17.05M | $-19.02M | $-38.84M | $-19.93M | $-17.27M | $-9.62M | $-12.27M | $-5.06M | $-5.09M | $-8.89M | $-3.01M | $-3.41M | $-1.96M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13603.45% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $9.00K | $12.00K | $11.00K | $11.00K | $9.00K | $11.00K | $5.00K | $5.00K | $25.00K | $306.00K | $-187.00K | $-93.00K | $- | $- | $- | $- | $- | $-3.01M | $-3.42M | $-1.96M |
| Net Income | $-10.44M | $-12.88M | $-10.46M | $-10.71M | $-7.90M | $-10.64M | $-10.11M | $-17.06M | $-19.04M | $-39.14M | $-19.74M | $-17.18M | $-9.62M | $-12.27M | $-5.06M | $-5.09M | $-8.89M | $-3.01M | $-3.41M | $-1.96M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | -13618.97% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.18 | $-0.22 | $-0.18 | $-0.23 | $-0.19 | $-0.25 | $-0.37 | $-0.72 | $-0.82 | $-1.68 | $-0.85 | $-0.74 | $-0.79 | $-0.53 | $-4.84 | $-0.22 | $-0.54 | $-0.18 | $-0.21 | $-0.12 |
| EPS Diluted | $-0.18 | $-0.22 | $-0.18 | $-0.23 | $-0.19 | $-0.25 | $-0.37 | $-0.72 | $-0.82 | $-1.68 | $-0.85 | $-0.74 | $-0.79 | $-0.53 | $-4.84 | $-0.22 | $-0.54 | $-0.18 | $-0.21 | $-0.12 |
| Weighted Average Shares Outstanding | 59.12M | 59.11M | 59.02M | 47.37M | 42.42M | 42.40M | 27.58M | 23.62M | 23.30M | 23.29M | 23.26M | 23.22M | 12.13M | 23.11M | 1.05M | 22.82M | 16.54M | 16.54M | 16.54M | 16.54M |
| Weighted Average Shares Outstanding Diluted | 59.12M | 59.11M | 59.02M | 47.37M | 42.42M | 42.40M | 27.58M | 23.62M | 23.30M | 23.29M | 23.26M | 23.22M | 12.13M | 23.11M | 1.05M | 22.82M | 16.54M | 16.54M | 16.54M | 16.54M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $49.46M | $49.26M | $45.92M | $146.28M | $79.40M |
| Short Term Investments | $43.72M | $33.85M | $44.36M | $- | $- |
| Cash and Short Term Investments | $93.18M | $83.11M | $90.28M | $146.28M | $79.40M |
| Net Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $1.54M | $4.86M | $2.70M | $6.28M | $1.39M |
| Total Current Assets | $94.73M | $87.96M | $92.98M | $149.42M | $80.79M |
| Property Plant Equipment Net | $34.00K | $59.00K | $98.00K | $38.00K | $56.00K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $59 | $98 | $38 | $56 |
| Goodwill and Intangible Assets | $- | $59 | $98 | $38 | $56 |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $866.00K | $1.07M | $1.09M | $31.96K | $64.94K |
| Total Non-Current Assets | $900.00K | $1.13M | $1.18M | $70.00K | $121.00K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $95.63M | $89.09M | $94.16M | $149.49M | $80.91M |
| Account Payables | $559.00K | $507.00K | $6.36M | $5.65M | $5.68M |
| Short Term Debt | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.91M | $3.64M | $9.33M | $3.14M | $1.11M |
| Total Current Liabilities | $4.47M | $4.14M | $15.69M | $8.79M | $6.79M |
| Long Term Debt | $31.13M | $30.14M | $29.43M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $2.00K | $8.00K | $97.20M |
| Total Non-Current Liabilities | $31.13M | $30.14M | $29.44M | $8.00K | $97.20M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $35.60M | $34.28M | $45.13M | $8.80M | $103.99M |
| Preferred Stock | $- | $- | $94.16M | $149.49M | $97.19M |
| Common Stock | $6.00K | $4.00K | $2.00K | $2.00K | $- |
| Retained Earnings | $-240.46M | $-195.97M | $-150.27M | $-55.19M | $-23.15M |
| Accumulated Other Comprehensive Income Loss | $61.00K | $9.00K | $-161.00K | $-149.49M | $- |
| Other Total Stockholders Equity | $300.41M | $250.77M | $199.46M | $46.39M | $-97.12M |
| Total Stockholders Equity | $60.02M | $54.81M | $49.03M | $140.70M | $-23.08M |
| Total Equity | $60.02M | $54.81M | $49.03M | $140.70M | $-23.08M |
| Total Liabilities and Stockholders Equity | $95.63M | $89.09M | $94.16M | $149.49M | $80.91M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $95.63M | $89.09M | $94.16M | $149.49M | $80.91M |
| Total Investments | $43.72M | $33.85M | $44.36M | $- | $- |
| Total Debt | $31.13M | $30.14M | $29.43M | $- | $- |
| Net Debt | $-18.33M | $-19.12M | $-16.48M | $-146.28M | $-79.40M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $49.46M | $48.20M | $59.45M | $90.63M | $49.26M | $54.88M | $106.33M | $55.90M | $45.92M | $52.59M | $53.88M | $53.01M | $146.28M | $155.20M | $158.02M | $69.91M | $79.40M | $-1.74M |
| Short Term Investments | $43.72M | $54.87M | $51.40M | $13.42M | $33.85M | $39.92M | $1.60M | $18.03M | $44.36M | $55.27M | $68.66M | $79.05M | $- | $- | $- | $- | $- | $3.48M |
| Cash and Short Term Investments | $93.18M | $103.07M | $110.85M | $104.05M | $83.11M | $94.80M | $107.92M | $73.93M | $90.28M | $107.86M | $122.54M | $132.06M | $146.28M | $155.20M | $158.02M | $69.91M | $79.40M | $1.74M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $1.54M | $2.25M | $2.72M | $3.84M | $4.86M | $4.00M | $1.50M | $1.91M | $2.70M | $4.43M | $2.29M | $2.19M | $6.28M | $6.47M | $1.87M | $1.20M | $1.39M | $- |
| Total Current Assets | $94.73M | $105.32M | $113.57M | $107.89M | $87.96M | $98.80M | $109.42M | $75.83M | $92.98M | $110.07M | $123.69M | $134.25M | $149.42M | $158.44M | $158.95M | $71.11M | $80.79M | $1.74M |
| Property Plant Equipment Net | $34.00K | $39.00K | $45.00K | $49.00K | $59.00K | $68.00K | $78.00K | $88.00K | $98.00K | $108.00K | $30.00K | $34.00K | $38.00K | $43.00K | $47.00K | $52.00K | $56.00K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $59 | $- | $- | $- | $98 | $- | $- | $- | $38.00K | $- | $- | $52.00K | $56.00K | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $59 | $- | $- | $- | $98 | $- | $- | $- | $38.00K | $- | $- | $52.00K | $56.00K | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $866.00K | $940.00K | $983.00K | $1.02M | $1.07M | $1.11M | $867.00K | $975.00K | $1.09M | $1.31M | $67.00K | $25.00K | $-6.00K | $40.00K | $65.00K | $548.00K | $9.00K | $-1.74M |
| Total Non-Current Assets | $900.00K | $979.00K | $1.03M | $1.07M | $1.13M | $1.18M | $945.00K | $1.06M | $1.18M | $1.42M | $97.00K | $59.00K | $70.00K | $83.00K | $112.00K | $652.00K | $121.00K | $-1.74M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $95.63M | $106.30M | $114.60M | $108.96M | $89.09M | $99.97M | $110.37M | $76.90M | $94.16M | $111.49M | $123.78M | $134.31M | $149.49M | $158.52M | $159.06M | $71.76M | $80.91M | $- |
| Account Payables | $559.00K | $2.63M | $344.00K | $435.00K | $507.00K | $3.64M | $5.24M | $4.04M | $6.36M | $5.67M | $1.30M | $882.00K | $5.65M | $5.43M | $939.00K | $672.00K | $5.68M | $- |
| Short Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Liabilities | $3.91M | $3.29M | $2.42M | $1.90M | $3.64M | $3.97M | $3.18M | $9.49M | $9.33M | $9.44M | $17.80M | $9.55M | $3.14M | $3.44M | $2.77M | $1.99M | $1.11M | $- |
| Total Current Liabilities | $4.47M | $5.93M | $2.76M | $2.33M | $4.14M | $7.61M | $8.42M | $13.53M | $15.69M | $15.10M | $19.09M | $10.44M | $8.79M | $8.88M | $3.71M | $2.67M | $6.79M | $- |
| Long Term Debt | $31.13M | $31.02M | $30.92M | $30.81M | $30.14M | $29.95M | $29.77M | $29.60M | $29.43M | $29.27M | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $2.00K | $3.00K | $5.00K | $7.00K | $8.00K | $10.00K | $12.00K | $97.20M | $97.20M | $- |
| Total Non-Current Liabilities | $31.13M | $31.02M | $30.92M | $30.81M | $30.14M | $29.95M | $29.77M | $29.60M | $29.44M | $29.27M | $5.00K | $7.00K | $8.00K | $10.00K | $12.00K | $97.20M | $97.20M | $- |
| Other Liabilities | $- | $- | $- | $- | $2 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $35.60M | $36.95M | $33.68M | $33.14M | $34.28M | $37.56M | $38.19M | $43.13M | $45.13M | $44.37M | $19.10M | $10.44M | $8.80M | $8.89M | $3.73M | $99.87M | $103.99M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $158.52M | $159.06M | $97.19M | $97.19M | $7.19M |
| Common Stock | $6.00K | $6.00K | $5.00K | $5.00K | $4.00K | $4.00K | $4.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $2.00K | $- | $- | $- |
| Retained Earnings | $-240.46M | $-230.02M | $-217.14M | $-206.68M | $-195.97M | $-188.07M | $-177.44M | $-167.32M | $-150.27M | $-131.22M | $-92.39M | $-72.46M | $-55.19M | $-45.56M | $-33.30M | $-28.24M | $-23.15M | $- |
| Accumulated Other Comprehensive Income Loss | $61.00K | $128.00K | $-26.00K | $-0 | $9.00K | $-1.00K | $-2.00K | $-51.00K | $-161.00K | $-258.00K | $-275.00K | $-204.00K | $-0 | $-158.52M | $-159.06M | $- | $- | $-5.87M |
| Other Total Stockholders Equity | $300.41M | $299.24M | $298.08M | $282.49M | $250.77M | $250.48M | $249.61M | $201.14M | $199.46M | $198.60M | $197.34M | $196.53M | $195.88M | $36.67M | $29.57M | $-97.06M | $-97.12M | $- |
| Total Stockholders Equity | $60.02M | $69.36M | $80.92M | $75.82M | $54.81M | $62.42M | $72.18M | $33.76M | $49.03M | $67.12M | $104.68M | $123.87M | $140.70M | $149.63M | $155.34M | $-28.11M | $-23.08M | $1.32M |
| Total Equity | $60.02M | $69.36M | $80.92M | $75.82M | $54.81M | $62.42M | $72.18M | $33.76M | $49.03M | $67.12M | $104.68M | $123.87M | $140.70M | $149.63M | $155.34M | $-28.11M | $-23.08M | $1.32M |
| Total Liabilities and Stockholders Equity | $95.63M | $106.30M | $114.60M | $108.96M | $89.09M | $99.97M | $110.37M | $76.90M | $94.16M | $111.49M | $123.78M | $134.31M | $149.49M | $158.52M | $159.06M | $71.76M | $80.91M | $1.32M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $95.63M | $106.30M | $114.60M | $108.96M | $89.09M | $99.97M | $110.37M | $76.90M | $94.16M | $111.49M | $123.78M | $134.31M | $149.49M | $158.52M | $159.06M | $71.76M | $80.91M | $1.32M |
| Total Investments | $43.72M | $54.87M | $51.40M | $13.42M | $33.85M | $39.92M | $1.60M | $18.03M | $44.36M | $55.27M | $68.66M | $79.05M | $- | $- | $- | $- | $- | $3.48M |
| Total Debt | $31.13M | $31.02M | $30.92M | $30.81M | $30.14M | $29.95M | $29.77M | $29.60M | $29.43M | $29.27M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Debt | $-18.33M | $-17.18M | $-28.53M | $-59.82M | $-19.12M | $-24.93M | $-76.55M | $-26.30M | $-16.48M | $-23.32M | $-53.88M | $-53.01M | $-146.28M | $-155.20M | $-158.02M | $-69.91M | $-79.40M | $1.74M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-44.48M | $-45.70M | $-95.08M | $-32.04M | $-17.27M |
| Depreciation and Amortization | $24.00K | $39.00K | $27.00K | $18.00K | $15.00K |
| Deferred Income Tax | $- | $- | $- | $-1.64M | $5.14M |
| Stock Based Compensation | $4.28M | $3.33M | $3.21M | $1.57M | $52.00K |
| Change in Working Capital | $3.84M | $-13.69M | $6.29M | $283.00K | $4.90M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $52.00K | $-5.86M | $711.00K | $-30.00K | $5.22M |
| Other Working Capital | $3.79M | $-7.83M | $5.58M | $313.00K | $-319.00K |
| Other Non Cash Items | $-22.00K | $-160.00K | $74.00K | $1.64M | $-5.14M |
| Net Cash Provided by Operating Activities | $-36.36M | $-56.18M | $-85.48M | $-30.17M | $-12.30M |
| Investments in Property Plant and Equipment | $- | $- | $-86.00K | $- | $-71.00K |
| Acquisitions Net | $- | $- | $44.31K | $- | $- |
| Purchases of Investments | $-69.56M | $-42.66M | $-112.31M | $- | $- |
| Sales Maturities of Investments | $61.20M | $54.20M | $68.00M | $- | $- |
| Other Investing Activities | $- | $- | $-44.31K | $- | $- |
| Net Cash Used for Investing Activities | $-8.37M | $11.54M | $-44.40M | $- | $-71.00K |
| Debt Repayment | $- | $- | $30.00M | $- | $- |
| Common Stock Issued | $44.21M | $46.50M | $- | $97.06M | $20.00K |
| Common Stock Repurchased | $-48.00K | $-24.00K | $-35.00K | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $779.00K | $1.50M | $-451.00K | $-11.00K | $90.01M |
| Net Cash Used Provided by Financing Activities | $44.94M | $47.98M | $29.51M | $97.05M | $90.03M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $209.00K | $3.34M | $-100.37M | $66.88M | $77.66M |
| Cash at End of Period | $49.46M | $49.26M | $45.92M | $146.28M | $79.40M |
| Cash at Beginning of Period | $49.26M | $45.92M | $146.28M | $79.40M | $1.74M |
| Operating Cash Flow | $-36.36M | $-56.18M | $-85.48M | $-30.17M | $-12.30M |
| Capital Expenditure | $- | $- | $-86.00K | $- | $-71.00K |
| Free Cash Flow | $-36.36M | $-56.18M | $-85.57M | $-30.17M | $-12.37M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-10.44M | $-12.88M | $-10.46M | $-10.71M | $-7.90M | $-10.64M | $-10.11M | $-17.06M | $-19.04M | $-38.84M | $-19.93M | $-17.27M | $-9.62M | $-12.27M | $-5.06M | $-5.09M | $-8.89M | $-3.01M | $-3.41M | $-1.96M |
| Depreciation and Amortization | $5.00K | $5.00K | $4.00K | $10.00K | $10.00K | $9.00K | $10.00K | $10.00K | $10.00K | $8.00K | $5.00K | $4.00K | $5.00K | $3.00K | $6.00K | $4.00K | $15.00K | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $-3.44M | $-204.00K | $-22.00K | $- | $- | $- | $- | $- | $-283.00K | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $1.18M | $1.15M | $1.05M | $902.00K | $284.00K | $843.00K | $744.00K | $1.46M | $859.00K | $883.00K | $837.00K | $627.00K | $689.00K | $659.00K | $158.00K | $65.00K | $16.00K | $15.00K | $12.00K | $9.00K |
| Change in Working Capital | $-675.00K | $3.67M | $1.45M | $-605.00K | $-4.28M | $-3.55M | $-4.61M | $-1.26M | $334.00K | $-6.31M | $9.66M | $2.61M | $14.00K | $3.70M | $1.02M | $-4.46M | $5.48M | $-1.73M | $799.00K | $356.00K |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $-2.07M | $2.29M | $-91.00K | $-72.00K | $-3.13M | $-1.60M | $1.20M | $-2.32M | $697.00K | $4.37M | $412.00K | $-4.76M | $214.00K | $4.75M | $15.00K | $-5.01M | $5.02M | $-1.06M | $1.05M | $209.00K |
| Other Working Capital | $1.40M | $1.39M | $1.54M | $-533.00K | $-1.14M | $-1.95M | $-5.80M | $2.32M | $-363.00K | $-10.68M | $9.25M | $7.37M | $-200.00K | $-1.05M | $1.01M | $552.00K | $456.00K | $-669.00K | $-253.00K | $147.00K |
| Other Non Cash Items | $-273.00K | $-334.00K | $906.00K | $1.82M | $3.14M | $180.00K | $172.00K | $12.00K | $-10.00K | $74.00K | $-3.00K | $13.00K | $283.00K | $-4.08M | $155.00K | $5.08M | $5.04M | $-1.06M | $1.05M | $209.00K |
| Net Cash Provided by Operating Activities | $-10.20M | $-8.38M | $-8.21M | $-9.57M | $-12.18M | $-13.36M | $-13.81M | $-16.83M | $-17.85M | $-44.18M | $-9.43M | $-14.02M | $-8.91M | $-7.90M | $-3.87M | $-9.48M | $-3.38M | $-4.73M | $-2.60M | $-1.59M |
| Investments in Property Plant and Equipment | $- | $-8.21M | $8.21M | $- | $- | $- | $- | $- | $-86.00K | $-86.00K | $- | $- | $- | $- | $- | $- | $-71.00K | $- | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $86.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-9.03M | $-13.57M | $-46.96M | $- | $-2.94M | $-39.72M | $- | $- | $-13.82M | $-13.25M | $-5.97M | $-79.27M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $20.50M | $10.70M | $9.30M | $20.70M | $9.50M | $1.60M | $16.50M | $26.60M | $25.00M | $26.70M | $16.30M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $8.21M | $-37.66M | $20.70K | $6.56K | $-38.12K | $16.50K | $26.60K | $86.00K | $-86.00K | $10.33K | $-79.27M | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $11.47M | $-2.87M | $-37.66M | $20.70M | $6.56M | $-38.12M | $16.50M | $26.60M | $11.18M | $13.37M | $10.33M | $-79.27M | $- | $- | $- | $- | $-71.00K | $- | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $14.55M | $29.66M | $- | $- | $46.50M | $- | $- | $- | $- | $19.00K | $91.98M | $5.08M | $91.98M | $-11.00K | $- | $20.00K | $- | $- |
| Common Stock Repurchased | $-4.00K | $-2.00K | $-16.00K | $-26.00K | $-2.00K | $-3.00K | $-7.00K | $-12.00K | $-4.00K | $-6.00K | $-25.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $12.00K | $147.00K | $620.00K | $- | $30.00K | $1.24M | $228.00K | $- | $29.53M | $- | $19.00K | $-91.98M | $- | $91.98M | $-11.00K | $64.83M | $- | $- | $25.18M |
| Net Cash Used Provided by Financing Activities | $-4.00K | $10.00K | $14.68M | $30.25M | $-2.00K | $27.00K | $47.73M | $216.00K | $-4.00K | $29.52M | $-25.00K | $19.00K | $- | $5.08M | $91.98M | $-11.00K | $64.83M | $20.00K | $- | $25.18M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $-53.33M | $53.33M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $1.26M | $-11.24M | $-31.18M | $41.38M | $-5.62M | $-51.45M | $50.42M | $9.98M | $-6.67M | $-1.29M | $874.00K | $-93.28M | $-8.91M | $-2.82M | $88.11M | $-9.49M | $61.37M | $-4.71M | $-2.60M | $23.59M |
| Cash at End of Period | $49.46M | $48.20M | $59.45M | $90.63M | $49.26M | $54.88M | $106.33M | $55.90M | $45.92M | $52.59M | $53.88M | $53.01M | $146.28M | $155.20M | $158.02M | $69.91M | $79.40M | $18.03M | $22.73M | $25.33M |
| Cash at Beginning of Period | $48.20M | $59.45M | $90.63M | $49.26M | $54.88M | $106.33M | $55.90M | $45.92M | $52.59M | $53.88M | $53.01M | $146.28M | $155.20M | $158.02M | $69.91M | $79.40M | $18.03M | $22.73M | $25.33M | $1.74M |
| Operating Cash Flow | $-10.20M | $-8.38M | $-8.21M | $-9.57M | $-12.18M | $-13.36M | $-13.81M | $-16.83M | $-17.85M | $-44.18M | $-9.43M | $-14.02M | $-8.91M | $-7.90M | $-3.87M | $-9.48M | $-3.38M | $-4.73M | $-2.60M | $-1.59M |
| Capital Expenditure | $- | $-8.21M | $8.21M | $- | $- | $- | $- | $- | $-86.00K | $-86.00K | $- | $- | $- | $- | $- | $- | $-71.00K | $- | $- | $- |
| Free Cash Flow | $-10.20M | $-8.38M | $- | $-9.57M | $-12.18M | $-13.36M | $-13.81M | $-16.83M | $-17.93M | $-44.27M | $-9.43M | $-14.02M | $-8.91M | $-7.90M | $-3.87M | $-9.48M | $-3.45M | $-4.73M | $-2.60M | $-1.59M |
Elevation Oncology Dividends
Explore Elevation Oncology's dividend history, including dividend yield, payout ratio, and historical payments.
Elevation Oncology News
Read the latest news about Elevation Oncology, including recent articles, headlines, and updates.
Elevation Oncology to Present Preclinical Data for EO-1022 at the American Association for Cancer Research (AACR) Annual Meeting 2025
-- Abstract accepted for late-breaking poster presentation – -- EO-1022 is a potentially differentiated HER3 ADC being developed for the treatment of solid tumors, including breast and non-small cell lung cancers -- -- On-track to file an Investigational New Drug (IND) application in 2026 – BOSTON , March 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it will present preclinical data for its novel HER3 ADC, EO-1022, in a late-breaking poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, being held April 25-30 in Chicago, Illinois. EO-1022 is an antibody drug conjugate (ADC) containing seribantumab, a fully human IgG2 anti-HER3 monoclonal antibody (mAb), which is site-specifically conjugated at glycan to the monomethyl auristatin E (MMAE) payload with a drug-to-antibody ratio (DAR) of 4.
Elevation Oncology to Discontinue Development of EO-3021; Advancing EO-1022, While Evaluating Strategic Options
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR Annual Meeting 2025 and to file an Investigational New Drug (IND) application in 2026 -- -- Updated clinical data of Claudin 18.2 ADC EO-3021 demonstrate ORR of 22.2% in biomarker-enriched patient population; electing to discontinue further development of EO-3021 -- -- Implementing workforce reduction of approximately 70%; cash runway extended into 2H 2026 -- BOSTON , March 20, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that it has elected to discontinue development of EO-3021. EO-3021 is a Claudin 18.2 antibody-drug conjugate (ADC), which Elevation Oncology was developing for the treatment of advanced, unresectable or metastatic gastric and gastroesophageal junction (GEJ) cancers.
Elevation Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Achievements
-- Dosing ongoing in Phase 1 clinical trial cohorts evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohorts in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohort of ongoing Phase 1 clinical trial in 2Q 2025 -- -- Preclinical data for HER3 ADC EO-1022 to be presented at American Association for Cancer Research (AACR) Annual Meeting 2025; plan to file an Investigational New Drug (IND) application in 2026 -- BOSTON , March 6, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2024, and highlighted recent business achievements. "We continue to advance our Claudin 18.2 ADC program, EO-3021, for the treatment of advanced gastric/GEJ cancer in the earlier lines settings," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology to Participate in Upcoming Investor Conferences
BOSTON , Feb. 25, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that members of management will participate in upcoming investor conferences in March: TD Cowen 45th Annual Health Care Conference. Fireside chat on Tuesday, March 4, 2025 at 9:10 AM ET in Boston, MA.
Elevation Oncology Provides Updates on Differentiated ADC Programs and Upcoming Milestones
-- Initiated dosing in Phase 1 clinical trial cohort evaluating Claudin 18.2 ADC EO-3021 in combination with ramucirumab or dostarlimab in patients with advanced gastric/gastroesophageal junction (GEJ) cancer -- -- Expect to report initial data from combination cohort in 4Q 2025 or 1Q 2026 -- -- On-track to report additional monotherapy data from dose escalation and expansion cohorts of ongoing Phase 1 clinical trial in 1H 2025 -- -- Plan to present preclinical data for HER3 ADC EO-1022 in 1H 2025 and file an Investigational New Drug (IND) application in 2026 -- BOSTON , Jan. 13, 2025 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced program updates and upcoming milestones. "We are rapidly advancing EO-3021 to address significant unmet needs in treating earlier lines of advanced gastric/GEJ cancer, where we believe we have a unique ability to improve on the standard of care," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology Expands Pipeline with Nomination of EO-1022, a HER3 ADC for the Treatment of HER3-expressing Solid Tumors
-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload – -- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload -- – Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 – BOSTON , Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the nomination of EO-1022 as its HER3 ADC development candidate. EO-1022 is currently progressing through preclinical development, and Elevation Oncology expects to file an investigational new drug (IND) application in 2026.
Elevation Oncology Licenses ADC Technology from Synaffix to Drive Pipeline Expansion
Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologies AMSTERDAM , Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, today announces that it has entered into a licensing agreement with Elevation Oncology, Inc., an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs.
Elevation Oncology Presents Preclinical Proof-of-Concept Data Supporting Combination Potential of EO-3021 with VEGFR2 or PD-1 Inhibitors at ESMO Immuno-Oncology Annual Congress 2024
-- Treatment with both combination regimens demonstrates synergistic anti-tumor activity, supporting planned combination strategy for EO-3021 in patients with gastric or gastroesophageal junction (GEJ) cancer – -- On-track to initiate dosing in combination portion of the ongoing Phase 1 clinical trial of EO-3021 in the fourth quarter of 2024 -- BOSTON , Dec. 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating the combination potential of EO-3021, a Claudin 18.2 antibody-drug conjugate (ADC), with VEGFR2 or PD-1 inhibitors. The data will be presented in a poster session at the European Society for Medical Oncology Immuno-Oncology Annual Congress 2024 (ESMO-IO), being held December 11-13, 2024, in Geneva, Switzerland.
Elevation Oncology to Present at the Piper Sandler 36th Annual Healthcare Conference
BOSTON , Nov. 26, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, President and Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 8:30 a.m.
Elevation Oncology Reports Third Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Promising initial Phase 1 data of EO-3021 reported in August highlighting 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Progressed into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to present preclinical data on the combination potential of EO-3021 with VEGFR2 or PD-1 inhibitors at ESMO Immuno-Oncology Annual Congress 2024 (ESMO-IO 2024) -- -- Expect to initiate dosing in combination portion of the Phase 1 trial of EO-3021 in 4Q 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 4Q 2024 -- BOSTON , Nov. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the third quarter ended September 30, 2024, and highlighted recent business achievements. "We continue to make significant progress with EO-3021, our potentially best-in-class Claudin 18.2 antibody-drug conjugate (ADC).
Empery Asset Management's Strategic Acquisition in Elevation Oncology
On September 30, 2024, Empery Asset Management, LP (Trades, Portfolio) made a significant addition to its investment portfolio by acquiring 4,000,000 shares of Elevation Oncology Inc (ELEV, Financial). This transaction, executed at a price of $0.5999 per share, represents a notable increase in the firm's stake in the biotechnology company.
Elevation Oncology Receives Fast Track Designation from the FDA for EO-3021 for the Treatment of Adult Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Expressing Claudin 18.2
BOSTON , Sept. 23, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation (FTD) to EO-3021, a differentiated antibody drug conjugate (ADC), for the treatment of patients with advanced or metastatic gastric and gastroesophageal junction (GC/GEJ) cancer expressing Claudin 18.2 that has progressed on or after prior therapy.
Elevation Oncology to Present at the H.C. Wainwright 26th Annual Global Investment Conference
BOSTON , Sept. 3, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J.
Undercovered Dozen: Elevation Oncology, Ivanhoe Mines, Union Pacific, Golub Capital +
We share 12 ideas published last week focused on stocks with less coverage on Seeking Alpha. A take on Easterly Government Properties suggests they offer reliable income similar to Treasury bonds with lower reinvestment risk. Bunge Global is seen as holding potential for market expansion opportunities despite its Q2 decline.
Why Is Penny Stock Elevation Oncology Trading Lower On Tuesday?
The stock of Elevation Oncology Inc. ELEV is trading lower on Tuesday after the company reported initial data from the dose escalation portion of the ongoing Phase 1 trial of EO-3021 in patients with advanced, unresectable, or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction, pancreatic, or esophageal cancers.
Elevation Oncology Reports Second Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Today announced promising initial data from Phase 1 clinical trial of EO-3021; 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer, with differentiated safety profile -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Secured clinical supply agreements to evaluate EO-3021 in combination with ramucirumab and dostarlimab with Lilly and GSK, respectively; expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- On-track to nominate development candidate for HER3-ADC program in 2H 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the second quarter ended June 30, 2024, and highlighted recent business achievements.
Elevation Oncology Announces Promising Initial Data from Phase 1 Clinical Trial Evaluating EO-3021 in Patients with Advanced Unresectable or Metastatic Solid Tumors Likely to Express Claudin 18.2
-- 42.8% confirmed ORR observed in Claudin 18.2-enriched subset of gastric and GEJ cancer -- -- EO-3021 demonstrated differentiated safety profile, with minimal MMAE-associated toxicities, including no neutropenia or peripheral neuropathy/ hypoesthesia -- -- Advancing into dose expansion portion of Phase 1 trial; additional monotherapy data expected in 1H 2025 -- -- Expect to initiate dosing in combination portion of Phase 1 trial by year-end 2024 -- -- Elevation Oncology to host conference call and webcast today at 8:30 a.m. ET -- BOSTON , Aug. 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced promising initial data from the dose escalation portion of the ongoing Phase 1 clinical trial of EO-3021 in patients with advanced, unresectable or metastatic solid tumors likely to express Claudin 18.2, including gastric, gastroesophageal junction (GEJ), pancreatic or esophageal cancers.
Elevation Oncology Announces Planned Combination Strategy for EO-3021 in Patients with Gastric or Gastroesophageal Junction Cancer
-- Plan to evaluate EO-3021 in combination with ramucirumab and dostarlimab; entered into clinical supply agreements with Lilly and GSK, respectively -- -- Expect to initiate dosing in combination portion of the Phase 1 trial by year-end 2024 -- -- Combination cohorts broaden market opportunity for EO-3021 to address unmet needs across second- and first-line gastric or gastroesophageal junction cancer settings -- -- On-track to provide update from ongoing Phase 1 clinical trial evaluating monotherapy EO-3021 by mid-3Q 2024, with additional data in 1H 2025 -- BOSTON , June 27, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced plans to expand its ongoing Phase 1 clinical trial to include two combination cohorts evaluating EO-3021 for the treatment of advanced gastric or gastroesophageal junction cancer. Following recently signed clinical supply agreements with Eli Lilly and Company (Lilly) and GSK, respectively, Elevation Oncology will evaluate EO-3021 in combination with ramucirumab, a VEGFR2 inhibitor, in second-line patients and in combination with dostarlimab, a PD-1 inhibitor, in the front-line setting.
Elevation Oncology to Present at the Citizens JMP Life Sciences Conference
BOSTON , May 7, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced that Joseph J. Ferra, Chief Executive Officer of Elevation Oncology, will participate in a fireside chat at the Citizens JMP Life Sciences Conference on Tuesday, May 14, 2024, at 11:30 am ET.
Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling
Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025. HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3. Nomination of ADC candidate for HER3-ADC clinical program expected in the 2nd half of 2024.
Elevation Oncology Reports First Quarter 2024 Financial Results and Highlights Recent Business Achievements
-- Enrollment ongoing in Phase 1 clinical trial of EO-3021 in the U.S. and Japan; expect to announce initial safety and efficacy data by mid-3Q 2024, with additional data in 1H 2025 -- -- Presented preclinical proof-of-concept data for HER3-ADC program at AACR Annual Meeting; on-track to nominate development candidate in 2H 2024 -- -- Raised $44.2 million year-to-date through ATM facility, extending cash runway into 2026 -- BOSTON , May 2, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2024, and highlighted recent business achievements. "In recent months, we focused on advancing our growing pipeline of differentiated ADCs, each with broad therapeutic potential, and extending our cash runway into 2026, beyond upcoming milestones for EO-3021 and our HER3-ADC program," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology: Continuing To Seek Footing As It Climbs (Rating Upgrade)
Elevation Oncology, Inc. has had a successful year, transitioning from the shelving of their seribantumab program to focusing on antibody-drug conjugates. Their flagship project, EO-3021, is a phase 1 study targeting Claudin-18.2 and has shown promising early results. Elevation Oncology is also exploring anti-HER3 ADCs and is close to nominating a candidate for clinical development in this area.
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024
-- On-track to nominate development candidate in 2024 -- BOSTON, April 8, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced new preclinical data demonstrating proof-of-concept for its differentiated HER3-ADC program. The data will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California.
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements
--Expanded ongoing Phase 1 clinical trial of EO-3021 globally, dosing first patient in Japan; on track to provide update in mid-2024 and to report additional data in 1H 2025 -- -- Preclinical proof-of-concept data for HER3-ADC program to be presented at AACR Annual Meeting; plan to nominate development candidate in 2024 – -- Raised approximately $17.0M in net proceeds through at-the-market (ATM) facility and refinanced debt facility with K2 Health Ventures; cash runway into the fourth quarter of 2025 -- BOSTON , March 6, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter and full-year ended December 31, 2023, and highlighted recent business achievements. "We are entering 2024 with tremendous momentum across our pipeline of differentiated ADC therapies," said Joseph Ferra, President and Chief Executive Officer of Elevation Oncology.
Elevation Oncology to Present Preclinical Proof-of-Concept Data for HER3-ADC Program at the American Association for Cancer Research (AACR) Annual Meeting 2024
-- Data support ongoing development of antibody-drug conjugate (ADC) program targeting HER3-expressing cancers – -- On-track to nominate development candidate in 2024 -- BOSTON , March 5, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical need, today announced that it will present preclinical proof-of-concept data for its differentiated HER3-targeting antibody-drug conjugate (ADC) program in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2024, being held April 5-10 in San Diego, California. "We are excited to share preclinical proof-of-concept data for our HER3-ADC program.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ELEV.